Skip to content
ClinCalc Pro
Menu
Opioid Analgesic (Transdermal)

Fentanyl Patch (Burns Pain)

Brand names: Durogesic, Matrifen, Mezolar

The transdermal fentanyl patch delivers a potent synthetic opioid through the skin for continuous management of stable, persistent severe pain, sometimes used for background pain in established burns once requirements are stable.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Fentanyl is a strong mu-opioid receptor agonist; the patch provides slow continuous absorption across the skin to maintain steady plasma concentrations.

Prescribing in practice

  • Transdermal fentanyl is only for opioid-tolerant patients with stable pain and is unsuitable for acute, unstable, or rapidly changing burns pain because of its slow onset and offset and the risk of fatal respiratory depression.
  • Heat — including fever, external warming, and the burn-injured hypermetabolic state — increases absorption and can cause dangerous opioid overdose, so the patch must not be applied near heat or to broken or burned skin.
  • A depot persists in the skin after removal, so effects and respiratory depression continue for many hours once the patch is taken off.

Monitoring

Monitor sedation level, respiratory rate, and pain control, with particular vigilance during fever or any external warming.

Counselling the patient

  • Apply only to intact, healthy skin and keep heat sources, hot baths, and electric blankets away from the patch.
  • Tell the team about excessive drowsiness or slow breathing, and dispose of used patches safely as they still contain drug.

Evidence & guidelines

Transdermal fentanyl is established for stable chronic severe pain; the MHRA has warned of the risk of fatal overdose from accidental exposure and heat-increased absorption.

Reference: NICE NG46; British Burns Association guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.